Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Takuya KishiKenji Sunagawa

Abstract

In patients and animals with hypertension, sympathetic nervous system (SNS) activation is present. We have demonstrated that angiotensin II type 1 receptor (AT₁R)-induced oxidative stress in the rostral ventrolateral medulla (RVLM), a vasomotor center in the brainstem, causes SNS activation in hypertensive rats. The aim of the present study was to determine whether orally administered AT₁R blockers (ARBs) inhibit SNS activation through an anti-oxidant effect via inhibition of AT₁R in the RVLM of hypertensive rats and, if so, whether the benefits are class effects of ARBs. Stroke-prone spontaneously hypertensive rats (SHRSPs), a hypertensive model with sympathoexcitation, were divided into four groups: SHRSPs treated with telmisartan (TLM), candesartan (CAN), or hydralazine (HYD) and a vehicle group (VEH). Although systolic blood pressure was reduced in the TLM, CAN and HYD groups to the same level, heart rate, SNS activation and oxidative stress in the RVLM were significantly lower in the TLM group only. The pressor effect caused by the microinjection of angiotensin II into the RVLM and the depressor effect caused by the microinjection of tempol, a superoxide dismutase mimetic, into the RVLM were both significantly smaller in T...Continue Reading

References

Feb 1, 1994·Psychological Reports·H P ParetteT E Smith
Jan 14, 1999·Journal of Hypertension·G Grassi
Apr 28, 2001·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Y LinI Abe
Sep 22, 2001·Hypertension·K T Weber
Nov 29, 2002·Circulation Research·Matthew C ZimmermanRobin L Davisson
Mar 27, 2003·Journal of Cardiovascular Pharmacology·Jun Ming WangFrans H H Leenen
Apr 5, 2003·The International Journal of Biochemistry & Cell Biology·M J McKinleyS Y Chai
Feb 12, 2004·Journal of Cardiovascular Pharmacology·Yoshitaka HirookaAkira Takeshita
Jul 20, 2004·Histochemistry and Cell Biology·Masaki UenoToshitaka Nakagawa
Jul 12, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Koji SakaiKenji Sunagawa
Nov 15, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Henry KrumMurray Esler
May 24, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yoshitaka HirookaKenji Sunagawa
Jun 9, 2006·Nature Reviews. Neuroscience·Patrice G Guyenet
Aug 10, 2006·Clinical and Experimental Pharmacology & Physiology·Valin RejaPaul M Pilowsky
Jan 25, 2008·Clinical and Experimental Hypertension : CHE·Takuya KishiKenji Sunagawa
Jul 16, 2008·Molecular and Cellular Endocrinology·I Van Liefde, G Vauquelin
Dec 23, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yasuaki KogaKenji Sunagawa
Aug 29, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MasudaSatoshi Umemura
Sep 19, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shuichiro ArakiKenji Sunagawa
Nov 28, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Nicolas PelischMasakazu Kohno
Dec 17, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masaki Mogi, Masatsugu Horiuchi
Apr 29, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshitaka HirookaKenji Sunagawa
May 27, 2010·Journal of Hypertension·Alain G Dupont, Sofie Brouwers
Jul 7, 2010·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Shin-ichiro MiuraKeijiro Saku
Jul 24, 2010·American Journal of Hypertension·Guido Grassi
Feb 19, 2011·American Journal of Hypertension·Cheri L McGowanJohn S Floras
Feb 25, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yoshitaka Hirooka
Apr 1, 2011·Current Hypertension Reports·Guido GrassiGiuseppe Mancia
Nov 15, 2011·Current Opinion in Nephrology and Hypertension·Guido GrassiGino Seravalle

❮ Previous
Next ❯

Citations

May 22, 2013·Current Hypertension Reports·Megumi Fujita, Toshiro Fujita
Mar 12, 2013·International Journal of Hypertension·Takuya Kishi, Yoshitaka Hirooka
Feb 20, 2013·Antioxidants & Redox Signaling·Samuel H H Chan, Julie Y H Chan
Jan 20, 2016·Current Hypertension Reports·Megumi Fujita, Toshiro Fujita
Apr 1, 2014·Clinical and Experimental Hypertension : CHE·Kengo IsegawaKenji Sunagawa
Oct 25, 2013·International Psychogeriatrics·Hiroko H DodgeJeffrey A Kaye
Jan 27, 2019·Journal of Neuroinflammation·Marta A MałkiewiczPaweł J Winklewski
Jan 9, 2021·Dose-response : a Publication of International Hormesis Society·Hussam MuradMamdooh Gari
Sep 24, 2015·Disease Models & Mechanisms·María González-NúñezJose M López-Novoa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.